LIQUIDIA CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.53 USD | +1.29% |
|
-5.72% | +4.16% |
| Apr. 01 | Liquidia Says US FDA Cleared to Approve Yutrepia to Treat Hypertension | MT |
| Apr. 01 | Liquidia's Yutrepia Cleared for Potential FDA Approval Following Court Ruling | DJ |
Presenter SpeechHarry Pearson (Analysts)Hello, all. Thank you for joining us this morning. My ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
12.53
USD
Average target price
23.86
USD
Spread / Average Target
+90.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.16% | 953M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- LQDA Stock
- News Liquidia Corporation
- Transcript : Liquidia Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 11
